A prospective, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61SQ in patients with relapsed/refractory multiple myeloma.
Subjects voluntarily participate in clinical research;
Age ≥18 years old;
Eastern Cooperative Oncology Group (ECOG) score 0-2;
Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria;
Received previous therapy targeting GPRC5D targets;
Prior antineoplastic therapy and meet exclusion criteria (before apheresis);
Subjects had Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;
First Affiliated Hospital of Wenzhou Medical University
Lead sponsor
Beijing Boren Hospital
Collaborator
First People's Hospital of Hangzhou
Collaborator